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Abstract: Background: Receptors located on enteroendocrine cells (EECs) of the colon can detect
nutrients in the lumen. These receptors regulate appetite through a variety of mechanisms, including
hormonal and neuronal signals. We assessed the effect of obesity on the expression of these G-protein
coupled receptors (GPCRs) and hormones at both mRNA and protein level. Methods: qPCR and
immunohistochemistry were used to examine colonic tissue from cohorts of patients from the
Netherlands (proximal and sigmoid tissue) and the United Kingdom (tissue from across the colon)
and patients were grouped by body mass index (BMI) value (BMI < 25 and BMI ≥ 25). Results: The
mRNA expression of the hormones/signaling molecules serotonin, glucagon, peptide YY (PYY), CCK
and somatostatin were not significantly different between BMI groups. GPR40 mRNA expression
was significantly increased in sigmoid colon samples in the BMI ≥ 25 group, but not proximal colon.
GPR41, GPR109a, GPR43, GPR120, GPRC6A, and CaSR mRNA expression were unaltered between
low and high BMI. At the protein level, serotonin and PYY containing cell numbers were similar in
high and low BMI groups. Enterochromaffin cells (EC) showed high degree of co-expression with
amino acid sensing receptor, CaSR while co-expression with PYY containing L-cells was limited,
regardless of BMI. Conclusions: While expression of medium/long chain fatty acid receptor GPR40
was increased in the sigmoid colon of the high BMI group, expression of other nutrient sensing GPCRs,
and expression profiles of EECs involved in peripheral mechanisms of appetite regulation were
unchanged. Collectively, these data suggest that in human colonic tissue, EEC and nutrient-sensing
receptor expression profiles are not affected despite changes to BMI.
Keywords: nutrient sensing; enteroendocrine cells (EECs); appetite regulation; G-protein coupled
receptors (GPCRs); obesity
1. Introduction
Obesity is a significant and growing health issue facing the Western world [1,2].
Obese adults are more susceptible to a wide range of comorbidities, including type 2 dia-
betes [3], metabolic disorders and abnormalities such as dyslipidaemia [4], cardiovascular
disease [5]—including hypertension [6], stroke [7]—and a variety of cancers [8].
Appetite is regulated to balance energy intake and expenditure by the release of
hunger and satiety signals [9]. Appetite regulation can begin before food enters the body;
the cephalic phase is initiated by sights and smells of food and by environmental effects
such as time of day [10]. Both mechanical and hormonal signals regulate food intake
via central control from brain centres of appetite regulation, including the solitary tract
nucleus in the brain stem [11,12]. Potent satiety hormones such as PYY and glucagon-like
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peptide 1 (GLP-1) are released from the small intestine to the colon, in response to dietary
nutrients [13]. The colon is the main source of peripheral serotonin [14] and holds the
highest number and diversity of microbiota, with bacterial by-products such as short chain
fatty acids (SCFA) playing a role in nutrient sensing and obesity. Hormones such as PYY,
CCK, and GLP-1 are released from the colon and can enter the circulation [15,16]. PYY
can stimulate neurons within the hypothalamic arcuate nucleus: orexigenic neurons co-
expresses agouti-related peptide (AgRP) and neuropeptide Y (NPY); anorexigenic neurons
release pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript
(CART) [9]. CCK can act on vagal fibres innervating the brain stem to alter gut motility,
secretions from the pancreas and gall bladder activation [9].
Enteroendocrine cells (EECs) are a subset of epithelial cells expressed throughout gas-
trointestinal tissues and are classified according to their hormone/peptide content [17,18].
EECs express nutrient-sensing receptors and respond to luminal contents, leading to the
release of anorectic hormones and mediators that act on the vagus nerve and hypothala-
mus, resulting in long-term satiation [18,19]. L cells, an EEC sub-type critical for appetite
regulation, co-secrete the potent anorectic hormones PYY and GLP-1, and are highly ex-
pressed in the colon [20,21]. PYY acts on receptors within the hypothalamus to inhibit
the release of the orexigenic peptide neuropeptide Y (NPY) [22]. These same receptors
are also found on peripheral vagal afferents [10] and are likely to drive PYY’s role in
regulating gastric acid secretion and gastrointestinal motility [22]. GLP-1 receptors are
also found within the hypothalamus and brain stem, where their activation reduces food
intake [23]. In obesity, circulating levels of PYY and GLP-1 are decreased [24,25]. Ente-
rochromaffin (EC) cells, a further population of EECs, secrete 95% of the body’s serotonin
in response to carbohydrate-rich foods and SCFAs [26]. Centrally released serotonin plays
an important role in modulating food cravings and mood [27,28] whilst serotonin from
the colon and periphery can activate small intestinal and colonic vagal afferent nerves to
modulate gastrointestinal secretion and motility [14,28]. Drugs that can act as serotonin
receptor agonists centrally have been shown to reduce weight gain in mice and caloric
intake in lean and obese humans via the hypothalamic melanocortin system [29]. Serotonin
is synthesised from tryptophan by the enzyme tryptophan hydroxylase 1 (TPH1), in a rate
limiting process [30]. Cholecystokinin (CCK), released by I cells [31], strongly reduces food
intake [32], and CCK administration reduces food intake in obese patients [33]. Finally,
somatostatin is expressed in D cells [34] and inhibits the release of anorectic hormones like
GLP-1 and PYY [35,36], demonstrating a critical cellular control mechanism. Collectively,
various EECs are required for the normal processes of appetite regulation.
Importantly, to activate EECs and induce release of hormones/peptides, nutrients
bind to and activate nutrient sensing G-protein coupled receptors (GPCRs) expressed on
EECs [37]. SCFAs can bind to GPCRs via GPR41 [38], GPR43 [39], and GPR109a [40],
medium/long chain fatty acids (M/LCFA) bind to GPR40 [41] and GPR120 [42] and amino
acids bind to CaSR [43] and GPRC6a [44]. These receptors are expressed throughout the
gastrointestinal tract, including the colon and rectum, in both mice and humans [45]. L-cells
express the SCFA receptors GPR43, GPR41 [46], and CaSR [47] and colonic ECs have been
shown to express GPR119, GPR120, GPR41, and GPR43 [48]. We have previously shown
that agonist action at GPR41, GPR40, and GPR119 induces colonic EEC activation [49] and,
importantly, that stimulation of GPR84 increases the release of GLP-1, PYY, and serotonin,
demonstrating functional modulation of L and EC cells [45].
There is evidence to suggest that obesity alters peripheral pathways of appetite regu-
lation. The mRNA expression and protein levels of GPR120 are decreased in the visceral
adipose tissue of obese individuals [50], while GPR120 knockout mice demonstrate an
obese phenotype [51]. mRNA expression of GPR41, GPR43, GPR40, and GPR120 increased
in diet-induced obese mice compared to mice on a normal diet [49]. Additionally, post-
prandial release of hormones is altered, with lower circulating levels of PYY and GLP-1
reported in obesity [9,52], with levels remaining low after 10 weeks of sustained weight
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loss [53]. Collectively, these data suggest that obesity may alter peripheral mechanisms of
appetite regulation.
The aim of this study was to assess expression profiles of EECs and nutrient-sensing
GPCRs, to determine if weight gain alters the physiology of nutrient sensing at the cellular
level, particularly in the colon.
2. Materials and Methods
2.1. Human Samples
Tissue specimens were collected in two centres: The Royal London Hospital, in
London, UK, and the Maastricht University Medical Centre (MUMC), in Maastricht,
the Netherlands.
In London, non-inflamed, non-cancerous (morphologically normal), full thickness,
and mucosal samples were taken from the ascending, transverse, and descending colon of
patients (n = 30) undergoing gastrointestinal cancer surgery.
In Maastricht, biopsies were taken from the right sided proximal and the sigmoid colon
of patients with irritable bowel syndrome (n = 30) participating in the Maastricht IBS cohort
study and undergoing routine colonoscopy. In addition, biopsies were taken from the
sigmoid colon of healthy controls (n = 7) participating in an interventional study (placebo
group). Inclusion and exclusion criteria of the Maastricht IBS cohort and the healthy
control group are described elsewhere [54,55]. Biopsies were placed in Eppendorf tubes
immediately and fresh frozen in liquid nitrogen to be stored at −80 ◦C until RNA isolation.
All participants gave written informed consent prior to inclusion. The studies were
approved by the East London and The City HA Local Research Ethics Committee (NREC
09/H0704/2) and the University of Maastricht Medical Ethics Committee, respectively,
and were performed in compliance with the revised Declaration of Helsinki (64th WMA
General Assembly, Fortaleza, Brazil, 2013). All samples collected were from fasted sub-
jects with tissue collection occurring in the morning. The study is registered in the US
National Library of Medicine (http://www.clinicaltrials.gov, NCT00775060, 2008, ac-
cessed on 5 March 2021). Patient and healthy control characteristics are presented in
Supplementary Tables S1 and S2, with the distribution of participant BMI from both re-
search locations shown in Supplementary Graphs S1 and S2.
2.2. Immunohistochemistry
Patient samples used for immunohistochemistry were obtained from the Royal Lon-
don Hospital as previously described. Full thickness samples were fixed in 4% paraformalde-
hyde/phosphate buffered saline (PBS) at 4 ◦C overnight. Tissue was cryoprotected in 30%
sucrose/PBS, then mounted in OCT embedding compound for cutting and subsequent
storage at −80 ◦C.
Cut tissue sections (10 µm) were washed with PBS, blocked with Trident Universal
Protein Blocking Reagent (animal serum free) (Insight Biotechnology limited GTX 30963)
and primary antibody was applied (Supplementary Table S3) for 18 h at 4 ◦C. Tissue was
then washed in PBS and incubated for 1 h with species-specific Alexa Fluor conjugated
secondary antibodies (Supplementary Table S4 (1:400)). Slides were cover-slipped with a
mounting medium containing diamidino-2-phenylindole (DAPI) (VECTASHIELD, Vector
laboratories H-1500). Negative controls were obtained by omitting the primary antibody.
Sections were visualised and imaged on an epifluorescence microscope (Leica DM4000
Epi-Fluorescence Microscope) and images were acquired on a monochrome CCD digital
camera system (Leica DFC365) using Metamorph imaging system software. Images were
analysed using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
MD, USA, https://imagej.nih.gov/ij/, 1997–2018, accessed on 5 March 2021).
Cell counts were performed on stained sections from a colonic region and positively
stained cells were manually counted. Counts were performed blinded to patient data,
including BMI. A minimum of 10 field of views (FOV) were taken in each section, the
number of cells and crypts were counted and the average value calculated for cells/crypt
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for each field of view and patient. Cells were counted based on the inclusion and exclusion
criteria listed in Table 1.
Table 1. Inclusion and exclusion criteria for counting of stained cells.
Inclusion Criteria Exclusion Criteria
Whole cells Parts of cells visible within fields of view (FOV)
Cells clearly distinguishable with nucleus (shape, size) Ambiguity in defining cell shape
Cells located within crypts Cells located outside of crypts
Levels of background low High background/noise across the FOV
2.3. Gene Expression Studies
Quantitative real-time reverse transcriptase PCR (RT-PCR) was used to assess the
relative expression of nutrient GPCRs and hormone/peptides in human colonic tissue
(Supplementary Table S6 for patient and tissue details).
Mucosal samples were stored in RNALater (Qiagen, Manchester, UK) at −80 ◦C prior
to gene expression experiments. RNA was extracted from tissues using a RNeasy Mini kit
(Qiagen). RNA quantity and quality were assessed using a NanoDrop machine. RNA was
reverse transcribed into cDNA using the Quantitech RT kit (Qiagen) or the High-Capacity
cDNA Reverse Transcription Kit with RNase inhibitor (Applied biosystems, Thermo Fisher
Scientific) for the London and Maastricht samples, respectively.
cDNA samples from Maastricht were reverse transcribed using MultiScribe Reverse
Transcriptase (ThermoFischer Scientific, Waltham, MA, USA). These samples were run
on TaqMan PCR (Thermofisher TaqMan Array Micro Fluidic card Cat# 4342249) using
a ViiA7 machine. For each patient, the relative gene expression of genes of interest and
2 positive controls (18s ribosomal RNA (18s) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH)) were calculated for each plate. The relative expression of mRNA from the
sigmoid and proximal colon was plotted separately against BMI. BMI values were used
to divide patients into normal weight patients (BMI < 25) and obese/overweight patients
(BMI ≥ 25). We also used regression analysis (Pearson r correlation and simple linear
regression) with BMI as the co-variant, and similar results were obtained (data not shown).
The patient group of BMI < 25 are all those patients below or equal to 24.9 BMI. Sigmoidal
and proximal colon samples were analysed separately. Supplementary Table S1 shows
the number of samples for each gene and colonic location and Supplementary Table S2 the
BMI distribution of these patients.
For samples from the Royal London Hospital, SYBR green primers were purchased
from Qiagen (Supplementary Table S5). Target gene expression was determined relative to
the endogenous control, 18s ribosomal RNA, using the comparative cycle threshold method
on an Applied Biosystems StepOnePLus real-time PCR system thermal cycling block.
2.4. Statistical Analysis
Data is expressed as mean ± SEM. Statistical analysis for mRNA expression and
cell counting was performed using unpaired t tests (Mann-Whitney test) (GraphPad
Prism, V.8, GraphPad Software Inc, San Diego, CA, USA), with p < 0.05 considered
statistically significant.
3. Results
3.1. The mRNA Expression of Hormones and Peptides Involved in Appetite Regulation Is
Unchanged between Healthy BMI (<25) and Overweight/Obese BMI (≥25)
In the proximal colon, there was no significant change in the expression of tryptophan
hydroxylase 1 (TPH1), glucagon, PYY or somatostatin, between the healthy BMI (<25) or
overweight/obese BMI group (≥25) (Figure 1A–E). We also assessed the expression of the
leptin receptor and observed no change in expression in either tissues between BMI groups.
The sigmoid colon showed no change in the mRNA expression of the genes assessed,
between the two BMI groups (Figure 1F–J).
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Figure 1. Relative mRNA expression of hormones and hormone receptors involved in satiety in the proximal and sigmoid
colon. mRNA expression (relative to 18s) of hormone markers in the proximal (A–E), (body mass index (BMI) < 25 n = 7,
BMI ≥ 25 n = 7), and sigmoid colon (F–J), (BMI < 25 n = 12, BMI ≥ 25 n = 12).
3.2. The Expression of PYY and Serotonin in Enterochromaffin and L-Cells Is Unchanged between
Healthy BMI (<25) and Overweight/Obese BMI (≥25)
In colonic tissue samples (from the Royal London Hospital, London, UK) serotonin
containing EC cells were present in colonic crypts in both the <25 and ≥25 BMI groups
(Figure 2A,B, respectively). PYY positive L-cells were also present in colonic crypts in both
BMI groups (Figure 2A,B). The quantification of EC and PYY cells showed no significant
difference between BMI groups (Figure 2C).
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significantly increased in the BMI ≥ 25 compared to BMI < 25 group (p = 0.0464) (Figure 3I).
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4. Discussion
We show that overall, overweight/obesity does not alter the gene expression of
hormones/peptides, nutrient-sensing GPCRs for SCFAs, the LCFA GPR120, or amino acids.
Similarly, at the protein level, the expression profile of EC and L cells is unchanged between
healthy and overweight/obese BMI groups. However, we do show a modest increase in
expression of the medium and long chain fatty acid receptor GPR40 in the sigmoid colon
of patients in the BMI ≥ 25 group.
We report that both PYY mRNA expression and the number of PYY containing L cells
are unchanged with increasing BMI. Our data suggests that the decreased circulating levels
of PYY described previously [24,25] are not caused by reduced PYY mRNA expression
or L-cell numbers, indicating that PYY release may be i paired. In addition, the mRNA
expression of glucagon (a marker of GLP-1 production) is not significantly different between
the two BMI groups, in either the sigmoid or proxi al colon. GLP-1 and PYY have been
shown to be co-expressed and co-released from secretory vesicles in L cells [23] therefore,
it is expected that their release profile will be similar. Indeed, it has been demonstrated
that ob se individuals have decre s d PYY an GLP-1 plasma levels that persisted for at
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least 12 months, despite weight loss [53]. Taken together with our data, this suggests that
while the cells and receptors regulating cell function are unchanged in obesity, the cellular
mechanisms leading to hormone release may be altered.
EC cells-mediated release of serotonin has been shown to be increased in obese vs.
non-obese patients but the colonic mRNA expression of TPH1, an enzyme critical for
serotonin production, is unchanged [56]. We similarly report no change in the expression
of TPH1 and show that EC numbers in human colon do not change in response to BMI.
These findings concur with a mouse study where EC numbers were unchanged in the
jejunum between high and low fat diet animals [9]. However, our group has previously
shown that expression of TPH-1 and the numbers of ECs were increased in the colons
of an obese mouse group compared to a wild-type group (though this increase did not
reach statistical significance) [49]. Collectively, these studies demonstrate that expression
of TPH1 mRNA and serotonin containing EC cells are stable in humans despite weight
changes. Furthermore, there may be changes at the genetic and protein levels in the murine
colon, compared to the human colon.
Other hormones, such as the anorexigenic hormones leptin and CCK, were unchanged
between the low and high BMI groups, as was the mRNA expression of somatostatin.
Leptin, produced by adipose tissue, is increased in obesity (in serum and plasma) [57]. Our
data shows that the colonic tissue has no impact on leptin changes. Unchanged levels of
CCK may reflect the small population in the colon, as I cells expressing CCK are found
primarily in the small intestine [31]. Somatostatin containing D cells are commonly found
in the duodenum and stomach, while colonic populations constitute 3–5% of cells [34];
therefore, changes to somatostatin expression may occur primarily outside of the colon.
mRNA expression of nutrient-sensing GPCRs which activate and stimulate release of
the cells described were similarly unchanged overall. However, there was a modest increase
in GPR40 mRNA expression in the sigmoid colon of the overweight/obese BMI group. No
change in GPR40 expression was observed in the proximal colon despite the previously
reported equal distribution between the proximal and distal colon [45]. GPR40 binds to
medium/long chain fatty acids and is expressed on human L cells, with agonist action
increasing the release of GLP-1 [58]. The difference between the proximal and sigmoid
colon expression of GPR40 may be attributed to its expression on L-cells, as density of these
cells increases along the colon, with highest levels found in the rectum [18]. Therefore, it
may be that greater numbers of cells expressing GPR40 are found in the sigmoid region,
accounting for the small difference in expression observed. GPR120, another important
MCFA sensing GPCR, was also unchanged in our study. This was a surprising result
as absence of the gene encoding GPR120 induces an obese phenotype in humans [59]
and mRNA expression is reportedly increased in the duodenum of obese and overweight
humans [60]. However, in diet-induced obese mice, our group has previously shown a
significant increase in mRNA expression of GPR120 and GPR40 between in obese mice [49].
Our data suggests that the colonic expression of GPR120 is stable and less likely to be
influenced by increased caloric intake as most nutrients are absorbed in the small intestine.
Although reports suggest that the microbiome is altered in obesity [61] and that
the luminal concentration of by-products of bacterial fermentation, i.e., SCFAs, may be
altered [62], we report no change in the mRNA expression of the SCFA receptors GPR43,
GPR41 or GPR109a. GRP43 and GPR41 knock-out mice have impaired L cell activity [63,64]
suggesting that these receptors are involved in peripheral mechanisms of satiety and
we have previously shown significant increase in expression of GPR41 or GPR43 in diet-
induced obesity [49]. However, data from this study in human colonic tissue suggests
that while the luminal environment may be altered in terms of bacterial populations and
subsequent fermentation products, the expression of SCFA GPCRs remains stable.
To understand whether changes to GPCR and EEC expression patterns were affected
by increasing BMI, we assessed co-expression via immunofluorescence. CaSR and EC
cells were highly co-localised while a small population of PYY containing L-cells also
expressed CaSR in human colonic tissue, regardless of BMI. We have previously reported a
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similar expression pattern of CaSR with PYY and serotonin in human colonic tissue [45].
Our data shows that obesity (BMI > 25) does not alter the expression of CaSR on EEC
types. Activation of CaSR expressed on EECs has been shown to release gastrin, CCK, and
GLP-1 [47,65] while L-cells from CaSR deficient mice show impaired release of CCK and
Ca2+ in response to L-phenylalanine [47], suggesting that CaSR is crucial for their release.
Our data suggests that agonists of CaSR may be an important target in obesity, as there is
conservation of the cellular pathways which may be targeted for L-cell activation.
An important limitation of the current study is that the release of hormones from EECs
cells or the ability of cells to become activated by nutrients binding to their corresponding
nutrient receptors was not assessed. Clinical data has shown that circulating levels of these
hormones is altered with obesity, therefore it is likely that hormone release is abrogated from
these cells [24,25]. Importantly, maintenance of long-term satiety is critically dependent on
PYY and GLP-1 [22,66]. Therefore, further studies are required to understand the capacity
of EC and L cells from overweight/obese individuals to release their hormone content in
response to nutrient stimulation. The focus of this study was the peripheral mechanisms
regulating appetite in order to understand changes to molecular machinery in response to
obesity. Lack of changes to expression of nutrient-sensing receptors and EECs does not
exclude possible changes to downstream pathways in the periphery, including changes to
hormone release profiles and afferent nerve activity, and warrants further investigation.
Overall, this study demonstrates that in human colonic tissue, the expression of
nutrient sensing GPCRs, satiety hormones and EEC does not significantly change in the
overweight/obese state. As previously discussed, obesity is characterised by an increased
caloric load, changes to the microbial and luminal environment in obesity. However, our
findings indicate that the expression pattern of the receptors and cells that sense luminal
content is stable in the human colon.
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